XML 47 R17.htm IDEA: XBRL DOCUMENT
v3.25.2

Income Taxes | 12 Months Ended
--- | ---
Jun. 30, 2025
Income Taxes [Abstract] |
INCOME TAXES | 10. INCOME TAXES The Company is not an operating company but a holding company incorporated in the State of Nevada and is considered U.S. tax resident under U.S. tax laws; accordingly, it is subject to U.S. tax laws at a statutory tax rate of 21%. The Company is subject to the State of Nevada tax laws at a tax rate of 0%. The Company’s net deferred income tax assets as of June 30, 2025and 2024 consist of net operating loss carry forwards. The net operating loss carry forwards for U.S. federal tax and Taiwan, China, Hong Kong tax purposes are available for carry forward indefinitely for use in offsetting taxable income. The U.S. federal net operating loss carry forward offset is limited to up to 80% of the taxable income. As of June 30, 2025 and 2024, the Company had total net operating loss carry forwards of approximately $13,167,716 and $8,767,393, respectively, which consists of China net operating loss carry forwards of $4,896,250 and $3,817,009, respectively, Taiwan net operating losses of $5,824,336 and $4,200,888, respectively, Hong Kong net operating loss carry forwards of $94,686 and $5,014, respectively, and US net operating loss carry forwards of $2,352,444 and $744,480, respectively. Taiwan The Company’s operating subsidiary, Advanced Biomed Inc. (Taiwan) is considered Taiwan tax resident enterprises under Taiwan tax laws; accordingly, it is subject to enterprise income tax on its taxable income as determined under Taiwan tax laws at a statutory tax rate of 20%. China The Company’s operating subsidiary, Shanghai Sglcell Biotech Co., Ltd. is considered PRC resident enterprises under Enterprise Income Tax Law of the PRC; accordingly, it is subject to enterprise income tax on their taxable income as determined under Enterprise Income Tax Law of the PRC at a statutory tax rate of 25%. Hong Kong Under the current Hong Kong Inland Revenue Ordinance, a two-tier corporate income tax system was implemented in Hong Kong, which is 8.25% for the first HK$2.0 million taxable income, and 16.5% for the subsequent taxable income generated from operations in Hong Kong. The Company’s subsidiary, Advanced Biomed HK Limited is considered Hong Kong tax resident under Hong Kong Tax Law; accordingly, it is subject to corporate income tax on its taxable income at 8.25% with nil and nil for the years ended June 30, 2025 and 2024. The income tax provision consists of the following component:
|  | For the years ended June 30, |
|  | 2025 |  |  | 2024 |
|  | US$ |  |  | US$ |
Income tax expense |  |  | - |  |  |  | - |
The following table reconciles the operating profit to the Company’s effective tax rate:
|  | For the years ended June 30, |
|  | 2025 |  |  | 2024 |
Loss before tax |  |  | (3,258,969 | ) |  |  | (2,782,278 | )
Statutory income tax rate |  |  | 21 | % |  |  | 21 | %
Income tax expense calculated at the statutory tax rate |  |  | - |  |  |  | - |
Effect of tax losses carry forwards |  |  | (2,890,755 | ) |  |  | (2,019,708 | )
Effect of subsidiaries foreign income |  |  | 2,890,755 |  |  |  | 2,019,708 |
Income tax expense |  |  | - |  |  |  | - |
Effective tax rate |  |  | - | % |  |  | - | %
The component of deferred tax assets are as follows:
|  | June 30, 2025 |  |  | June 30, 2024 |
|  | US$ |  |  | US$ |
Net operating losses carry forward |  |  | 2,890,755 |  |  |  | 2,019,708 |
Valuation allowance |  |  | (2,890,755 | ) |  |  | (2,019,708 | )
Deferred tax assets, net |  |  | - |  |  |  | - |
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the cumulative earnings and projected future taxable income in making this assessment. Recovery of substantially all of the Company’s deferred tax assets is dependent upon the generation of future income, exclusive of reversing taxable temporary differences. A reconciliation of the differences between the federal income tax rate and the effective tax rate is as follows: State of Nevada
|  | For the years ended June 30, |
|  | 2025 |  |  | 2024 |
Tax at federal statutory rate |  |  | 21 | % |  |  | 21 | %
Changes in valuation allowances |  |  | (21 | )% |  |  | (21 | )%
Provision for taxes |  |  | - | % |  |  | - | %
Taiwan
|  | For the years ended June 30, |
|  | 2025 |  |  | 2024 |
Tax at federal statutory rate |  |  | 21 | % |  |  | 21 | %
Different foreign subsidiary tax rate impact |  |  | (1 | )% |  |  | (1 | )%
Changes in valuation allowances |  |  | (20 | )% |  |  | (20 | )%
Provision for taxes |  |  | - | % |  |  | - | %
China
|  | For the years ended June 30, |
|  | 2025 |  |  | 2024 |
Tax at federal statutory rate |  |  | 21 | % |  |  | 21 | %
Different foreign subsidiary tax rate impact |  |  | 4 | % |  |  | 4 | %
Changes in valuation allowances |  |  | (25 | )% |  |  | (25 | )%
Provision for taxes |  |  | - | % |  |  | - | %
Hong Kong
|  | For the years ended June 30, |
|  | 2025 |  |  | 2024 |
Tax at federal statutory rate |  |  | 21 | % |  |  | 21 | %
Different foreign subsidiary tax rate impact |  |  | (12.75 | )% |  |  | (12.75 | )%
Changes in valuation allowances |  |  | (8.25 | )% |  |  | (8.25 | )%
Provision for taxes |  |  | - | % |  |  | - | %

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 740 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 740 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration